Drug Approval | June 27, 2022
Astellas’s update on the Fortis clinical trial of AT845 in adults for pompe disease
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Acceptance based on results from the phase 3 KEYNOTE-091 trial
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
